Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-845-579-5705

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

T: +1-347-918-3531

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Onychomycosis Treatment Market Snapshot (2023 to 2033)

The global onychomycosis treatment market is expected to hold a value worth US$ 4,738.3 million in 2023. From 2023 to 2033, the onychomycosis treatment market is likely to exhibit a CAGR of 8.4% while garnering a value worth US$ 10,608.8 million. The market's growth can be attributed to the growing prevalence of diabetes, which results in high risks of nail fungus infection.

Data Points Key Statistics
Expected Market Value (2023) US$ 4,738.3 million
Anticipated Forecast Value (2033) US$ 10,608.8 million
Projected Growth Rate (2023 to 2033) 8.4%

Onychomycosis is a fungal infection that occurs in the fingernails and toenails that can result in chronic pain, disfigurement, and discomfort. The disease is characterized by symptoms such as whitish to yellow-brown discoloration, distortion in the shape of nails, and ragged and crumbly texture of the nails.

It is generally diagnosed through potassium, oxygen, and hydrogen examination, culture, and histopathological examinations of nail clippings and nail biopsies and is treated with laser therapy and photodynamic therapies.

The growing prevalence of chronic illnesses like human immunodeficiency virus (HIV), diabetes and peripheral artery disease (PAD), and onychomycosis is one of the key factors driving the market growth during the forecast period. Also, the expanding geriatric population, prone to such disorders due to the weakened immune system, is likely to fuel the demand for treatment during the forecast period.

Besides, the condition is highly prevalent among millennials and adults owing to the rising exposure to public swimming pools and the usage of tight clothes, shoes, and socks. Other factors adding to the market growth include topical nail lacquers and ointments to maintain nail hygiene, along with the significant developments in the healthcare infrastructure as likely to augment the market size in the forthcoming time.

Additionally, increasing approvals for novel products in the industry are expected to grow the market in the assessment period. For instance, in 2022, Zydus Lifesciences received approval from the US health regulator to market an antifungal Efinaconazole Topical Solution. The company received the final approval from the United States FDA to market the product. Such factors are likely to widen the market growth scope during the forecast period.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Global Onychomycosis Treatment Market Revenue Analysis 2018 to 2022 Vs. Future Outlook 2023 to 2033

The expansion of the market can be attributed to increasing awareness about the threats of onychomycosis and increasing adoption of drug therapies, which are likely to have contributed significantly to the development of the market.

Further, increasing cases of age-related onychomycosis is another cause that is expected to have benefitted the market. Also, increasing approval by the regulatory authorities is another vital factor that has contributed to the market growth. For instance, in July 2021, Lupin received approval to launch Tavaborole Topical Solution, 5 % in the United States from the United States FDA.

Tavaborole Topical Solution is a generic equivalent of Kerydin Topical Solution, 5%, of Anacor Pharmaceuticals, and is an oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails owing to Trichophyton rubrum or Trichophyton mentagrophytes.

From 2023 to 2033, the global onychomycosis treatment market is anticipated to display a CAGR of 8.4%. The expansion of the market during the aforementioned period can be attributed to the increasing prevalence of diabetes across the globe. Diabetic patients are susceptible to toenail fungus.

Various studies and research have been performed to understand whether diabetic people experience a greater risk of onychomycosis than those without diabetes; most studies concluded that they do. Such factors are expected to benefit the market during the forecast period.

Factors Propelling the Global Onychomycosis Treatment Market

Increasing Shift toward Topical Solutions to Benefit the Market

As per the analysis, the increasing preference for topical treatment solutions is expected to play a significant role in developing the market during the forecast period. Per a survey conducted on dermatologists and podiatrists in the United States, 7 out of 10 doctors avoid prescribing oral terbinafine due to the risk of liver damage.

Another factor contributing to the market growth is the increasing prevalence of toenail infection caused due to onychomycosis. As per a study, about 10% of the world’s general population suffers from onychomycosis, with 35 to 40 million Americans being infected with nail fungus. This is anticipated to favor market growth in the coming time.

Also, the growing approval of medications by the regulatory authorities is anticipated to augment the market size significantly during the forecast period.

For instance, in 2020, Bausch Health Companies Inc. and its dermatology business, Ortho Dermatologics, obtained FDA approval for a supplemental New Drug Application (sNDA) for Jublia (efinaconazole) topical solution, 10%, a treatment for onychomycosis, a fungal infection of the toenails. Such factors are expected to benefit the market during the forecast period.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Factors Hindering the Global Onychomycosis Treatment Industry

Lack of Awareness to Hinder the Market

The most significant factor affecting the market negatively includes the lack of awareness regarding the condition. People tend to ignore the symptoms of onychomycosis, such as decolorization, thickening of the nails, and separation of nails from the nail bed.

Because of this, the nail fungal infection remains undiagnosed. Further, people refrain from the treatment as they are not aware of the prevailing condition. Thus, the market is likely to suffer in the coming time. Another factor hampering the market is the side effects of the onychomycosis treatment drugs. Thus, the market is projected to suffer in the assessment period.

Key Trends in the Global Onychomycosis Treatment Industry

Increasing Research and Development Investment by Pharmaceutical Companies to Offer Remunerative Opportunities

The disease's growing prevalence has resulted in a significant investment in research and development by pharmaceutical companies for the development of novel therapeutics. Various available topical treatment solutions fail to penetrate deep inside the nail bed and, thus, do not cure the infection completely. Various players are investing significantly to offer novel drugs to meet the growing demand to cure the condition.

For instance, Hexima is conducting a phase I/IIa clinical study on HXP124, a plant defensin anti-fungal molecule for dermatophytes onychomycosis treatment. HXP124 witnessed a greater penetration rate as compared to Jublia and Kerydin. Such factors are anticipated to offer remunerative opportunities for expansion in the forthcoming time.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Segmentation Analysis

Hospital Pharmacies Segment Likely to Dominate Other Segments in the Onychomycosis Industry

Availability of Medicines in Hospitals to Benefit the Segmental Growth in the Forecast Period

According to the analysis, the hospital segment is anticipated to be valued at more than US$ 2.2 Billion in 2022. The development of the segment can be attributed to the availability of medicines and other medical facilities there.

Also, an increase in privately owned clinics and the rise in dermatologists and podiatrists are likely to develop the segment in the forecast period.

Why are Drugs Expected to Dominate the Global Onychomycosis Treatment?

Increasing Research and Development on Drugs to Favor Segmental Growth

Segment Drugs
Market Share % (2022) 59.4%

According to the analysis, the drug segment is expected to claim more than 59.4% of the global revenue during the forecast period. The domination of the segment can be attributed to the increasing focus on research and development and the convenience of this treatment type. Thus, the segment is likely to witness notable growth during the forecast period.

Regional Analysis

Increasing Research and Development on Onychomycosis in North America Benefitting the Global Market

Region North America
Market Share % (2022) 33.6%

According to the analysis, the onychomycosis treatment market in North America is expected to dominate the global market during the forecast period. The region is projected to account for a more than 33.6% market share in 2023.

The United States is anticipated to significantly contribute to developing the industry in the assessment period. The domination of the regional market can be attributed to the increasing initiatives of players to study the disease.

For instance, in October 2020, Pfizer Inc. announced that it had commenced clinical studies on onychomycosis. The first phase involved research on whether the AN2690 topical solution is effective for onychomycosis of the toenail.

The second stage involved an open-label study to understand the safety and pharmacokinetics of the tavaborole 5% topical solution to treat distal subungual onychomycosis of the toenail in children and adolescents.

Another factor contributing to the market growth is the increasing cases of diabetes. As per CDC, 37.3 million Americans, or 1 in 10, have diabetes. Such stats are expected to benefit the market in the forecast period.

Government Initiatives Likely to Benefit the Onychomycosis Treatment Industry in Europe

Region Europe
Market Share % (2022) 28.8%

As per the study, the European onychomycosis treatment market is anticipated to display a market share of more than 28.8% in 2023. The United Kingdom is projected to make a significant contribution to developing the regional market during the forecast period. The development of the regional market can be attributed to the growing initiatives by the government to spread awareness among citizens.

For instance, the British Association of Dermatologists offers patient information leaflets for fungal infections of the nails. Such factors are expected to benefit the onychomycosis treatment market in Europe during the forecast period.

Launch of New Products in the Asia Pacific Supporting the Expansion of the Onychomycosis Treatment Market

Countries Market Share % (2022)
China 13.2%
India 10.8%

According to the study, the Asia Pacific is projected to exhibit maximum market growth during the forecast period. The rapid development of the regional market can be attributed to various developing countries making significant contributions to advancing healthcare services.

For instance, in 2020, Kaken Pharmaceuticals Co., Ltd. announced the launch of Jublia in Hong Kong for dermatophytic onychomycosis treatment. Such initiatives are expected to drive the market in the Asia Pacific during the forecast period.

Contribution of Startups in Developing the Onychomycosis Treatment Industry

Blueberry Therapeutics, Richpoint Pharma (Canada), ToeFX (Canada), and Hallux (US) are emerging names in the global onychomycosis treatment industry.

Recent Development in the Startup Landscape:

In December 2020, Hallux, a United States-based player, completed a US$ 7.1 million Series A expected to allow it to conduct Phase IIa clinical trials of its drug/device combination product for onychomycosis.

Competition Analysis

Key players in the global onychomycosis treatment market include Teva Pharmaceutical Industries Ltd., Sanofi S.A., Valent Pharmaceutical, Galderma, Johnson & Johnson, Novartis AG, Moberg Pharma AB, Cardinal Health, Inc., Pfizer Inc., Almirall, S.A., Bayer AG, Viatris Inc., GlaxoSmithKline plc, Cipla Ltd., and Dr. Reddy’s Laboratories Ltd.

Recent Developments in the Market Include:

  • In November 2021, Sanofi announced the acquisition of Kadmon Holdings. The acquisition further develops the growth and expansion of the General Medicines portfolio. Sanofi concluded its acquisition of Kadmon through the merger of a wholly owned subsidiary of Sanofi with and into Kadmon, pursuant to Section 251 of the General Corporation Law of the State of Delaware, with Kadmon continuing as the surviving corporation and becoming an indirect, wholly-owned subsidiary of Sanofi.
  • In December 2021, Pfizer Inc. and Arena Pharmaceuticals, Inc. announced that the companies had inked an agreement under which Pfizer may acquire Arena, a clinical-stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases.

Onychomycosis Treatment Market - Scope of Report

Attributes Details
Onychomycosis Treatment Market Forecast Period 2023 to 2033
Historical Data Available for 2018 to 2022
Onychomycosis Treatment Market Analysis US$ million in value
Onychomycosis Treatment Market - Key Regions Covered
  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • The Middle East & Africa
Key Countries Covered
  • The United States
  • Canada
  • Germany
  • The United Kingdom
  • France
  • Italy
  • Spain
  • Poland
  • Russia
  • China
  • Japan
  • South Korea
  • India
  • Thailand
  • Malaysia
  • Indonesia
  • Australia
  • New Zealand
  • GCC
  • South Africa
Onychomycosis Treatment Market - Key Segments Covered
  • Treatment Type
  • Indication
  • Age Group
  • Gender
  • Distribution Channel
  • Region
Key Companies Profiled
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi S.A.
  • Medimetriks Pharmaceuticals, Inc.
  • Galderma
  • Johnson & Johnson
  • Novartis AG
  • Moberg Pharma AB
  • Cardinal Health, Inc.
  • Pfizer Inc.
  • Almirall, S.A.
  • Bayer AG
  • Viatris Inc.
  • GlaxoSmithKline plc
  • Cipla Ltd.
  • Dr. Reddy’s Laboratories Ltd
Report Coverage Market Forecast, brand share analysis, competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives
Customization & Pricing Available upon Request

Key Segments in The Global Onychomycosis Treatment Industry

Treatment Type:

  • Drugs
    • Oral
      • Rx
      • OTC
    • Topical
      • Rx
      • OTC
  • Lasers
    • C02 Ablative Lasers
    • Nd: YAG Lasers
    • Dual-wavelength near-infrared Lasers
  • Photodynamic Therapy

Disease Indication:

  • Distal Subungual Onychomycosis
  • White Superficial Onychomycosis
  • Proximal Subungual Onychomycosis
  • Candidal Onychomycosis
  • Total Dystrophic Onychomycosis

Age Group:

  • 0 to 18 Years
  • 18 to 39 Years
  • 40 to 64 Years
  • 65 Years & Above

Gender:

  • Male
  • Female

Distribution Channel:

  • Institutional Sales
    • Hospitals
    • Dermatology Clinics
  • Retail Sales
    • Retail Pharmacies
    • Drug Stores
    • Mail Order Pharmacies & Online Sales

Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • The Middle East and Africa (MEA)

Frequently Asked Questions

How big is the onychomycosis treatment market?

The onychomycosis treatment market is worth US$ 4,738.3 million in 2023.

What is the growth forecast for the onychomycosis treatment market?

The onychomycosis treatment market is predicted to rise at an 8.4% CAGR through 2033.

How big will be the onychomycosis treatment market by 2033?

The onychomycosis treatment market is estimated to be worth US$ 10,608.8 million by 2033.

What was the onychomycosis treatment market’s leading treatment type in 2022?

The drugs segment leads the onychomycosis treatment market with 59.4% shares acquired in 2022.

Which country holds high lucrativeness in the onychomycosis treatment market?

China holds prominence, with 13.2% of shares captured in 2022.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Treatment Type, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment Type, 2023 to 2033

        5.3.1. Drugs

            5.3.1.1. Oral

            5.3.1.2. Topical

        5.3.2. Lasers

            5.3.2.1. C02 Ablative Lasers

            5.3.2.2. Nd: YAG Lasers

            5.3.2.3. Dual-wavelength near-infrared Lasers

        5.3.3. Photodynamic Therapy

    5.4. Y-o-Y Growth Trend Analysis By Treatment Type, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Treatment Type, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease Indication

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Disease Indication, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Disease Indication, 2023 to 2033

        6.3.1. Distal Subungual Onychomycosis

        6.3.2. White Superficial Onychomycosis

        6.3.3. Proximal Subungual Onychomycosis

        6.3.4. Candidal Onychomycosis

        6.3.5. Total Dystrophic Onychomycosis

    6.4. Y-o-Y Growth Trend Analysis By Disease Indication, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Disease Indication, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Age Group

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By Age Group , 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Age Group , 2023 to 2033

        7.3.1. 0-18 Years

        7.3.2. 18-39 Years

        7.3.3. 40-64 Years

        7.3.4. 65 Years & Above

    7.4. Y-o-Y Growth Trend Analysis By Age Group , 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By Age Group , 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Gender

    8.1. Introduction / Key Findings

    8.2. Historical Market Size Value (US$ Million) Analysis By Gender, 2018 to 2022

    8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Gender, 2023 to 2033

        8.3.1. Male

        8.3.2. Female

    8.4. Y-o-Y Growth Trend Analysis By Gender, 2018 to 2022

    8.5. Absolute $ Opportunity Analysis By Gender, 2023 to 2033

9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

    9.1. Introduction / Key Findings

    9.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022

    9.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033

        9.3.1. Institutional Sales

            9.3.1.1. Hospitals

            9.3.1.2. Dermatology Clinics

        9.3.2. Retail Sales

            9.3.2.1. Retail Pharmacies

            9.3.2.2. Drug Stores

            9.3.2.3. Mail Order Pharmacies & Online Sales

    9.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022

    9.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033

10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    10.1. Introduction

    10.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    10.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        10.3.1. North America

        10.3.2. Latin America

        10.3.3. Western Europe

        10.3.4. Eastern Europe

        10.3.5. South Asia and Pacific

        10.3.6. East Asia

        10.3.7. Middle East and Africa

    10.4. Market Attractiveness Analysis By Region

11. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. USA.

            11.2.1.2. Canada

        11.2.2. By Treatment Type

        11.2.3. By Disease Indication

        11.2.4. By Age Group

        11.2.5. By Gender

        11.2.6. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Treatment Type

        11.3.3. By Disease Indication

        11.3.4. By Age Group

        11.3.5. By Gender

        11.3.6. By Distribution Channel

    11.4. Key Takeaways

12. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. Brazil

            12.2.1.2. Mexico

            12.2.1.3. Rest of Latin America

        12.2.2. By Treatment Type

        12.2.3. By Disease Indication

        12.2.4. By Age Group

        12.2.5. By Gender

        12.2.6. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Treatment Type

        12.3.3. By Disease Indication

        12.3.4. By Age Group

        12.3.5. By Gender

        12.3.6. By Distribution Channel

    12.4. Key Takeaways

13. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. Germany

            13.2.1.2. United Kingdom.

            13.2.1.3. France

            13.2.1.4. Spain

            13.2.1.5. Italy

            13.2.1.6. Rest of Western Europe

        13.2.2. By Treatment Type

        13.2.3. By Disease Indication

        13.2.4. By Age Group

        13.2.5. By Gender

        13.2.6. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Treatment Type

        13.3.3. By Disease Indication

        13.3.4. By Age Group

        13.3.5. By Gender

        13.3.6. By Distribution Channel

    13.4. Key Takeaways

14. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. Poland

            14.2.1.2. Russia

            14.2.1.3. Czech Republic

            14.2.1.4. Romania

            14.2.1.5. Rest of Eastern Europe

        14.2.2. By Treatment Type

        14.2.3. By Disease Indication

        14.2.4. By Age Group

        14.2.5. By Gender

        14.2.6. By Distribution Channel

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Treatment Type

        14.3.3. By Disease Indication

        14.3.4. By Age Group

        14.3.5. By Gender

        14.3.6. By Distribution Channel

    14.4. Key Takeaways

15. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. India

            15.2.1.2. Bangladesh

            15.2.1.3. Australia

            15.2.1.4. New Zealand

            15.2.1.5. Rest of South Asia and Pacific

        15.2.2. By Treatment Type

        15.2.3. By Disease Indication

        15.2.4. By Age Group

        15.2.5. By Gender

        15.2.6. By Distribution Channel

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Treatment Type

        15.3.3. By Disease Indication

        15.3.4. By Age Group

        15.3.5. By Gender

        15.3.6. By Distribution Channel

    15.4. Key Takeaways

16. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        16.2.1. By Country

            16.2.1.1. China

            16.2.1.2. Japan

            16.2.1.3. South Korea

        16.2.2. By Treatment Type

        16.2.3. By Disease Indication

        16.2.4. By Age Group

        16.2.5. By Gender

        16.2.6. By Distribution Channel

    16.3. Market Attractiveness Analysis

        16.3.1. By Country

        16.3.2. By Treatment Type

        16.3.3. By Disease Indication

        16.3.4. By Age Group

        16.3.5. By Gender

        16.3.6. By Distribution Channel

    16.4. Key Takeaways

17. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    17.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    17.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        17.2.1. By Country

            17.2.1.1. GCC Countries

            17.2.1.2. South Africa

            17.2.1.3. Israel

            17.2.1.4. Rest of MEA

        17.2.2. By Treatment Type

        17.2.3. By Disease Indication

        17.2.4. By Age Group

        17.2.5. By Gender

        17.2.6. By Distribution Channel

    17.3. Market Attractiveness Analysis

        17.3.1. By Country

        17.3.2. By Treatment Type

        17.3.3. By Disease Indication

        17.3.4. By Age Group

        17.3.5. By Gender

        17.3.6. By Distribution Channel

    17.4. Key Takeaways

18. Key Countries Market Analysis

    18.1. USA.

        18.1.1. Pricing Analysis

        18.1.2. Market Share Analysis, 2022

            18.1.2.1. By Treatment Type

            18.1.2.2. By Disease Indication

            18.1.2.3. By Age Group

            18.1.2.4. By Gender

            18.1.2.5. By Distribution Channel

    18.2. Canada

        18.2.1. Pricing Analysis

        18.2.2. Market Share Analysis, 2022

            18.2.2.1. By Treatment Type

            18.2.2.2. By Disease Indication

            18.2.2.3. By Age Group

            18.2.2.4. By Gender

            18.2.2.5. By Distribution Channel

    18.3. Brazil

        18.3.1. Pricing Analysis

        18.3.2. Market Share Analysis, 2022

            18.3.2.1. By Treatment Type

            18.3.2.2. By Disease Indication

            18.3.2.3. By Age Group

            18.3.2.4. By Gender

            18.3.2.5. By Distribution Channel

    18.4. Mexico

        18.4.1. Pricing Analysis

        18.4.2. Market Share Analysis, 2022

            18.4.2.1. By Treatment Type

            18.4.2.2. By Disease Indication

            18.4.2.3. By Age Group

            18.4.2.4. By Gender

            18.4.2.5. By Distribution Channel

    18.5. Germany

        18.5.1. Pricing Analysis

        18.5.2. Market Share Analysis, 2022

            18.5.2.1. By Treatment Type

            18.5.2.2. By Disease Indication

            18.5.2.3. By Age Group

            18.5.2.4. By Gender

            18.5.2.5. By Distribution Channel

    18.6. United Kingdom.

        18.6.1. Pricing Analysis

        18.6.2. Market Share Analysis, 2022

            18.6.2.1. By Treatment Type

            18.6.2.2. By Disease Indication

            18.6.2.3. By Age Group

            18.6.2.4. By Gender

            18.6.2.5. By Distribution Channel

    18.7. France

        18.7.1. Pricing Analysis

        18.7.2. Market Share Analysis, 2022

            18.7.2.1. By Treatment Type

            18.7.2.2. By Disease Indication

            18.7.2.3. By Age Group

            18.7.2.4. By Gender

            18.7.2.5. By Distribution Channel

    18.8. Spain

        18.8.1. Pricing Analysis

        18.8.2. Market Share Analysis, 2022

            18.8.2.1. By Treatment Type

            18.8.2.2. By Disease Indication

            18.8.2.3. By Age Group

            18.8.2.4. By Gender

            18.8.2.5. By Distribution Channel

    18.9. Italy

        18.9.1. Pricing Analysis

        18.9.2. Market Share Analysis, 2022

            18.9.2.1. By Treatment Type

            18.9.2.2. By Disease Indication

            18.9.2.3. By Age Group

            18.9.2.4. By Gender

            18.9.2.5. By Distribution Channel

    18.10. Poland

        18.10.1. Pricing Analysis

        18.10.2. Market Share Analysis, 2022

            18.10.2.1. By Treatment Type

            18.10.2.2. By Disease Indication

            18.10.2.3. By Age Group

            18.10.2.4. By Gender

            18.10.2.5. By Distribution Channel

    18.11. Russia

        18.11.1. Pricing Analysis

        18.11.2. Market Share Analysis, 2022

            18.11.2.1. By Treatment Type

            18.11.2.2. By Disease Indication

            18.11.2.3. By Age Group

            18.11.2.4. By Gender

            18.11.2.5. By Distribution Channel

    18.12. Czech Republic

        18.12.1. Pricing Analysis

        18.12.2. Market Share Analysis, 2022

            18.12.2.1. By Treatment Type

            18.12.2.2. By Disease Indication

            18.12.2.3. By Age Group

            18.12.2.4. By Gender

            18.12.2.5. By Distribution Channel

    18.13. Romania

        18.13.1. Pricing Analysis

        18.13.2. Market Share Analysis, 2022

            18.13.2.1. By Treatment Type

            18.13.2.2. By Disease Indication

            18.13.2.3. By Age Group

            18.13.2.4. By Gender

            18.13.2.5. By Distribution Channel

    18.14. India

        18.14.1. Pricing Analysis

        18.14.2. Market Share Analysis, 2022

            18.14.2.1. By Treatment Type

            18.14.2.2. By Disease Indication

            18.14.2.3. By Age Group

            18.14.2.4. By Gender

            18.14.2.5. By Distribution Channel

    18.15. Bangladesh

        18.15.1. Pricing Analysis

        18.15.2. Market Share Analysis, 2022

            18.15.2.1. By Treatment Type

            18.15.2.2. By Disease Indication

            18.15.2.3. By Age Group

            18.15.2.4. By Gender

            18.15.2.5. By Distribution Channel

    18.16. Australia

        18.16.1. Pricing Analysis

        18.16.2. Market Share Analysis, 2022

            18.16.2.1. By Treatment Type

            18.16.2.2. By Disease Indication

            18.16.2.3. By Age Group

            18.16.2.4. By Gender

            18.16.2.5. By Distribution Channel

    18.17. New Zealand

        18.17.1. Pricing Analysis

        18.17.2. Market Share Analysis, 2022

            18.17.2.1. By Treatment Type

            18.17.2.2. By Disease Indication

            18.17.2.3. By Age Group

            18.17.2.4. By Gender

            18.17.2.5. By Distribution Channel

    18.18. China

        18.18.1. Pricing Analysis

        18.18.2. Market Share Analysis, 2022

            18.18.2.1. By Treatment Type

            18.18.2.2. By Disease Indication

            18.18.2.3. By Age Group

            18.18.2.4. By Gender

            18.18.2.5. By Distribution Channel

    18.19. Japan

        18.19.1. Pricing Analysis

        18.19.2. Market Share Analysis, 2022

            18.19.2.1. By Treatment Type

            18.19.2.2. By Disease Indication

            18.19.2.3. By Age Group

            18.19.2.4. By Gender

            18.19.2.5. By Distribution Channel

    18.20. South Korea

        18.20.1. Pricing Analysis

        18.20.2. Market Share Analysis, 2022

            18.20.2.1. By Treatment Type

            18.20.2.2. By Disease Indication

            18.20.2.3. By Age Group

            18.20.2.4. By Gender

            18.20.2.5. By Distribution Channel

    18.21. GCC Countries

        18.21.1. Pricing Analysis

        18.21.2. Market Share Analysis, 2022

            18.21.2.1. By Treatment Type

            18.21.2.2. By Disease Indication

            18.21.2.3. By Age Group

            18.21.2.4. By Gender

            18.21.2.5. By Distribution Channel

    18.22. South Africa

        18.22.1. Pricing Analysis

        18.22.2. Market Share Analysis, 2022

            18.22.2.1. By Treatment Type

            18.22.2.2. By Disease Indication

            18.22.2.3. By Age Group

            18.22.2.4. By Gender

            18.22.2.5. By Distribution Channel

    18.23. Israel

        18.23.1. Pricing Analysis

        18.23.2. Market Share Analysis, 2022

            18.23.2.1. By Treatment Type

            18.23.2.2. By Disease Indication

            18.23.2.3. By Age Group

            18.23.2.4. By Gender

            18.23.2.5. By Distribution Channel

19. Market Structure Analysis

    19.1. Competition Dashboard

    19.2. Competition Benchmarking

    19.3. Market Share Analysis of Top Players

        19.3.1. By Regional

        19.3.2. By Treatment Type

        19.3.3. By Disease Indication

        19.3.4. By Age Group

        19.3.5. By Gender

        19.3.6. By Distribution Channel

20. Competition Analysis

    20.1. Competition Deep Dive

        20.1.1. Teva Pharmaceutical Industries Ltd.

            20.1.1.1. Overview

            20.1.1.2. Product Portfolio

            20.1.1.3. Profitability by Market Segments

            20.1.1.4. Sales Footprint

            20.1.1.5. Strategy Overview

                20.1.1.5.1. Marketing Strategy

        20.1.2. Sanofi S.A.

            20.1.2.1. Overview

            20.1.2.2. Product Portfolio

            20.1.2.3. Profitability by Market Segments

            20.1.2.4. Sales Footprint

            20.1.2.5. Strategy Overview

                20.1.2.5.1. Marketing Strategy

        20.1.3. Medimetriks Pharmaceuticals, Inc.

            20.1.3.1. Overview

            20.1.3.2. Product Portfolio

            20.1.3.3. Profitability by Market Segments

            20.1.3.4. Sales Footprint

            20.1.3.5. Strategy Overview

                20.1.3.5.1. Marketing Strategy

        20.1.4. Galderma

            20.1.4.1. Overview

            20.1.4.2. Product Portfolio

            20.1.4.3. Profitability by Market Segments

            20.1.4.4. Sales Footprint

            20.1.4.5. Strategy Overview

                20.1.4.5.1. Marketing Strategy

        20.1.5. Johnson & Johnson

            20.1.5.1. Overview

            20.1.5.2. Product Portfolio

            20.1.5.3. Profitability by Market Segments

            20.1.5.4. Sales Footprint

            20.1.5.5. Strategy Overview

                20.1.5.5.1. Marketing Strategy

        20.1.6. Novartis AG

            20.1.6.1. Overview

            20.1.6.2. Product Portfolio

            20.1.6.3. Profitability by Market Segments

            20.1.6.4. Sales Footprint

            20.1.6.5. Strategy Overview

                20.1.6.5.1. Marketing Strategy

        20.1.7. Moberg Pharma AB

            20.1.7.1. Overview

            20.1.7.2. Product Portfolio

            20.1.7.3. Profitability by Market Segments

            20.1.7.4. Sales Footprint

            20.1.7.5. Strategy Overview

                20.1.7.5.1. Marketing Strategy

        20.1.8. Cardinal Health, Inc.

            20.1.8.1. Overview

            20.1.8.2. Product Portfolio

            20.1.8.3. Profitability by Market Segments

            20.1.8.4. Sales Footprint

            20.1.8.5. Strategy Overview

                20.1.8.5.1. Marketing Strategy

        20.1.9. Pfizer Inc.

            20.1.9.1. Overview

            20.1.9.2. Product Portfolio

            20.1.9.3. Profitability by Market Segments

            20.1.9.4. Sales Footprint

            20.1.9.5. Strategy Overview

                20.1.9.5.1. Marketing Strategy

        20.1.10. Almirall, S.A.

            20.1.10.1. Overview

            20.1.10.2. Product Portfolio

            20.1.10.3. Profitability by Market Segments

            20.1.10.4. Sales Footprint

            20.1.10.5. Strategy Overview

                20.1.10.5.1. Marketing Strategy

        20.1.11. Bayer AG

            20.1.11.1. Overview

            20.1.11.2. Product Portfolio

            20.1.11.3. Profitability by Market Segments

            20.1.11.4. Sales Footprint

            20.1.11.5. Strategy Overview

                20.1.11.5.1. Marketing Strategy

        20.1.12. Viatris Inc.

            20.1.12.1. Overview

            20.1.12.2. Product Portfolio

            20.1.12.3. Profitability by Market Segments

            20.1.12.4. Sales Footprint

            20.1.12.5. Strategy Overview

                20.1.12.5.1. Marketing Strategy

        20.1.13. GlaxoSmithKline plc

            20.1.13.1. Overview

            20.1.13.2. Product Portfolio

            20.1.13.3. Profitability by Market Segments

            20.1.13.4. Sales Footprint

            20.1.13.5. Strategy Overview

                20.1.13.5.1. Marketing Strategy

        20.1.14. Cipla Ltd.

            20.1.14.1. Overview

            20.1.14.2. Product Portfolio

            20.1.14.3. Profitability by Market Segments

            20.1.14.4. Sales Footprint

            20.1.14.5. Strategy Overview

                20.1.14.5.1. Marketing Strategy

        20.1.15. Dr. Reddy’s Laboratories Ltd

            20.1.15.1. Overview

            20.1.15.2. Product Portfolio

            20.1.15.3. Profitability by Market Segments

            20.1.15.4. Sales Footprint

            20.1.15.5. Strategy Overview

                20.1.15.5.1. Marketing Strategy

21. Assumptions & Acronyms Used

22. Research Methodology

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033

Table 2: Global Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033

Table 3: Global Market Value (US$ Million) Forecast by Disease Indication, 2018 to 2033

Table 4: Global Market Value (US$ Million) Forecast by Age Group , 2018 to 2033

Table 5: Global Market Value (US$ Million) Forecast by Gender, 2018 to 2033

Table 6: Global Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 7: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 8: North America Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033

Table 9: North America Market Value (US$ Million) Forecast by Disease Indication, 2018 to 2033

Table 10: North America Market Value (US$ Million) Forecast by Age Group , 2018 to 2033

Table 11: North America Market Value (US$ Million) Forecast by Gender, 2018 to 2033

Table 12: North America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 13: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 14: Latin America Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033

Table 15: Latin America Market Value (US$ Million) Forecast by Disease Indication, 2018 to 2033

Table 16: Latin America Market Value (US$ Million) Forecast by Age Group , 2018 to 2033

Table 17: Latin America Market Value (US$ Million) Forecast by Gender, 2018 to 2033

Table 18: Latin America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 19: Western Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 20: Western Europe Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033

Table 21: Western Europe Market Value (US$ Million) Forecast by Disease Indication, 2018 to 2033

Table 22: Western Europe Market Value (US$ Million) Forecast by Age Group , 2018 to 2033

Table 23: Western Europe Market Value (US$ Million) Forecast by Gender, 2018 to 2033

Table 24: Western Europe Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 25: Eastern Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 26: Eastern Europe Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033

Table 27: Eastern Europe Market Value (US$ Million) Forecast by Disease Indication, 2018 to 2033

Table 28: Eastern Europe Market Value (US$ Million) Forecast by Age Group , 2018 to 2033

Table 29: Eastern Europe Market Value (US$ Million) Forecast by Gender, 2018 to 2033

Table 30: Eastern Europe Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 31: South Asia and Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 32: South Asia and Pacific Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033

Table 33: South Asia and Pacific Market Value (US$ Million) Forecast by Disease Indication, 2018 to 2033

Table 34: South Asia and Pacific Market Value (US$ Million) Forecast by Age Group , 2018 to 2033

Table 35: South Asia and Pacific Market Value (US$ Million) Forecast by Gender, 2018 to 2033

Table 36: South Asia and Pacific Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 37: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 38: East Asia Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033

Table 39: East Asia Market Value (US$ Million) Forecast by Disease Indication, 2018 to 2033

Table 40: East Asia Market Value (US$ Million) Forecast by Age Group , 2018 to 2033

Table 41: East Asia Market Value (US$ Million) Forecast by Gender, 2018 to 2033

Table 42: East Asia Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 43: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 44: Middle East and Africa Market Value (US$ Million) Forecast by Treatment Type, 2018 to 2033

Table 45: Middle East and Africa Market Value (US$ Million) Forecast by Disease Indication, 2018 to 2033

Table 46: Middle East and Africa Market Value (US$ Million) Forecast by Age Group , 2018 to 2033

Table 47: Middle East and Africa Market Value (US$ Million) Forecast by Gender, 2018 to 2033

Table 48: Middle East and Africa Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

List of Charts

Figure 1: Global Market Value (US$ Million) by Treatment Type, 2023 to 2033

Figure 2: Global Market Value (US$ Million) by Disease Indication, 2023 to 2033

Figure 3: Global Market Value (US$ Million) by Age Group , 2023 to 2033

Figure 4: Global Market Value (US$ Million) by Gender, 2023 to 2033

Figure 5: Global Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 6: Global Market Value (US$ Million) by Region, 2023 to 2033

Figure 7: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033

Figure 8: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 9: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 10: Global Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033

Figure 11: Global Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033

Figure 12: Global Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033

Figure 13: Global Market Value (US$ Million) Analysis by Disease Indication, 2018 to 2033

Figure 14: Global Market Value Share (%) and BPS Analysis by Disease Indication, 2023 to 2033

Figure 15: Global Market Y-o-Y Growth (%) Projections by Disease Indication, 2023 to 2033

Figure 16: Global Market Value (US$ Million) Analysis by Age Group , 2018 to 2033

Figure 17: Global Market Value Share (%) and BPS Analysis by Age Group , 2023 to 2033

Figure 18: Global Market Y-o-Y Growth (%) Projections by Age Group , 2023 to 2033

Figure 19: Global Market Value (US$ Million) Analysis by Gender, 2018 to 2033

Figure 20: Global Market Value Share (%) and BPS Analysis by Gender, 2023 to 2033

Figure 21: Global Market Y-o-Y Growth (%) Projections by Gender, 2023 to 2033

Figure 22: Global Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 23: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 24: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 25: Global Market Attractiveness by Treatment Type, 2023 to 2033

Figure 26: Global Market Attractiveness by Disease Indication, 2023 to 2033

Figure 27: Global Market Attractiveness by Age Group , 2023 to 2033

Figure 28: Global Market Attractiveness by Gender, 2023 to 2033

Figure 29: Global Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 30: Global Market Attractiveness by Region, 2023 to 2033

Figure 31: North America Market Value (US$ Million) by Treatment Type, 2023 to 2033

Figure 32: North America Market Value (US$ Million) by Disease Indication, 2023 to 2033

Figure 33: North America Market Value (US$ Million) by Age Group , 2023 to 2033

Figure 34: North America Market Value (US$ Million) by Gender, 2023 to 2033

Figure 35: North America Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 36: North America Market Value (US$ Million) by Country, 2023 to 2033

Figure 37: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 38: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 39: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 40: North America Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033

Figure 41: North America Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033

Figure 42: North America Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033

Figure 43: North America Market Value (US$ Million) Analysis by Disease Indication, 2018 to 2033

Figure 44: North America Market Value Share (%) and BPS Analysis by Disease Indication, 2023 to 2033

Figure 45: North America Market Y-o-Y Growth (%) Projections by Disease Indication, 2023 to 2033

Figure 46: North America Market Value (US$ Million) Analysis by Age Group , 2018 to 2033

Figure 47: North America Market Value Share (%) and BPS Analysis by Age Group , 2023 to 2033

Figure 48: North America Market Y-o-Y Growth (%) Projections by Age Group , 2023 to 2033

Figure 49: North America Market Value (US$ Million) Analysis by Gender, 2018 to 2033

Figure 50: North America Market Value Share (%) and BPS Analysis by Gender, 2023 to 2033

Figure 51: North America Market Y-o-Y Growth (%) Projections by Gender, 2023 to 2033

Figure 52: North America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 53: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 54: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 55: North America Market Attractiveness by Treatment Type, 2023 to 2033

Figure 56: North America Market Attractiveness by Disease Indication, 2023 to 2033

Figure 57: North America Market Attractiveness by Age Group , 2023 to 2033

Figure 58: North America Market Attractiveness by Gender, 2023 to 2033

Figure 59: North America Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 60: North America Market Attractiveness by Country, 2023 to 2033

Figure 61: Latin America Market Value (US$ Million) by Treatment Type, 2023 to 2033

Figure 62: Latin America Market Value (US$ Million) by Disease Indication, 2023 to 2033

Figure 63: Latin America Market Value (US$ Million) by Age Group , 2023 to 2033

Figure 64: Latin America Market Value (US$ Million) by Gender, 2023 to 2033

Figure 65: Latin America Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 66: Latin America Market Value (US$ Million) by Country, 2023 to 2033

Figure 67: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 68: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 69: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 70: Latin America Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033

Figure 71: Latin America Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033

Figure 72: Latin America Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033

Figure 73: Latin America Market Value (US$ Million) Analysis by Disease Indication, 2018 to 2033

Figure 74: Latin America Market Value Share (%) and BPS Analysis by Disease Indication, 2023 to 2033

Figure 75: Latin America Market Y-o-Y Growth (%) Projections by Disease Indication, 2023 to 2033

Figure 76: Latin America Market Value (US$ Million) Analysis by Age Group , 2018 to 2033

Figure 77: Latin America Market Value Share (%) and BPS Analysis by Age Group , 2023 to 2033

Figure 78: Latin America Market Y-o-Y Growth (%) Projections by Age Group , 2023 to 2033

Figure 79: Latin America Market Value (US$ Million) Analysis by Gender, 2018 to 2033

Figure 80: Latin America Market Value Share (%) and BPS Analysis by Gender, 2023 to 2033

Figure 81: Latin America Market Y-o-Y Growth (%) Projections by Gender, 2023 to 2033

Figure 82: Latin America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 83: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 84: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 85: Latin America Market Attractiveness by Treatment Type, 2023 to 2033

Figure 86: Latin America Market Attractiveness by Disease Indication, 2023 to 2033

Figure 87: Latin America Market Attractiveness by Age Group , 2023 to 2033

Figure 88: Latin America Market Attractiveness by Gender, 2023 to 2033

Figure 89: Latin America Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 90: Latin America Market Attractiveness by Country, 2023 to 2033

Figure 91: Western Europe Market Value (US$ Million) by Treatment Type, 2023 to 2033

Figure 92: Western Europe Market Value (US$ Million) by Disease Indication, 2023 to 2033

Figure 93: Western Europe Market Value (US$ Million) by Age Group , 2023 to 2033

Figure 94: Western Europe Market Value (US$ Million) by Gender, 2023 to 2033

Figure 95: Western Europe Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 96: Western Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 97: Western Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 98: Western Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 99: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 100: Western Europe Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033

Figure 101: Western Europe Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033

Figure 102: Western Europe Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033

Figure 103: Western Europe Market Value (US$ Million) Analysis by Disease Indication, 2018 to 2033

Figure 104: Western Europe Market Value Share (%) and BPS Analysis by Disease Indication, 2023 to 2033

Figure 105: Western Europe Market Y-o-Y Growth (%) Projections by Disease Indication, 2023 to 2033

Figure 106: Western Europe Market Value (US$ Million) Analysis by Age Group , 2018 to 2033

Figure 107: Western Europe Market Value Share (%) and BPS Analysis by Age Group , 2023 to 2033

Figure 108: Western Europe Market Y-o-Y Growth (%) Projections by Age Group , 2023 to 2033

Figure 109: Western Europe Market Value (US$ Million) Analysis by Gender, 2018 to 2033

Figure 110: Western Europe Market Value Share (%) and BPS Analysis by Gender, 2023 to 2033

Figure 111: Western Europe Market Y-o-Y Growth (%) Projections by Gender, 2023 to 2033

Figure 112: Western Europe Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 113: Western Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 114: Western Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 115: Western Europe Market Attractiveness by Treatment Type, 2023 to 2033

Figure 116: Western Europe Market Attractiveness by Disease Indication, 2023 to 2033

Figure 117: Western Europe Market Attractiveness by Age Group , 2023 to 2033

Figure 118: Western Europe Market Attractiveness by Gender, 2023 to 2033

Figure 119: Western Europe Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 120: Western Europe Market Attractiveness by Country, 2023 to 2033

Figure 121: Eastern Europe Market Value (US$ Million) by Treatment Type, 2023 to 2033

Figure 122: Eastern Europe Market Value (US$ Million) by Disease Indication, 2023 to 2033

Figure 123: Eastern Europe Market Value (US$ Million) by Age Group , 2023 to 2033

Figure 124: Eastern Europe Market Value (US$ Million) by Gender, 2023 to 2033

Figure 125: Eastern Europe Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 126: Eastern Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 127: Eastern Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 128: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 129: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 130: Eastern Europe Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033

Figure 131: Eastern Europe Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033

Figure 132: Eastern Europe Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033

Figure 133: Eastern Europe Market Value (US$ Million) Analysis by Disease Indication, 2018 to 2033

Figure 134: Eastern Europe Market Value Share (%) and BPS Analysis by Disease Indication, 2023 to 2033

Figure 135: Eastern Europe Market Y-o-Y Growth (%) Projections by Disease Indication, 2023 to 2033

Figure 136: Eastern Europe Market Value (US$ Million) Analysis by Age Group , 2018 to 2033

Figure 137: Eastern Europe Market Value Share (%) and BPS Analysis by Age Group , 2023 to 2033

Figure 138: Eastern Europe Market Y-o-Y Growth (%) Projections by Age Group , 2023 to 2033

Figure 139: Eastern Europe Market Value (US$ Million) Analysis by Gender, 2018 to 2033

Figure 140: Eastern Europe Market Value Share (%) and BPS Analysis by Gender, 2023 to 2033

Figure 141: Eastern Europe Market Y-o-Y Growth (%) Projections by Gender, 2023 to 2033

Figure 142: Eastern Europe Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 143: Eastern Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 144: Eastern Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 145: Eastern Europe Market Attractiveness by Treatment Type, 2023 to 2033

Figure 146: Eastern Europe Market Attractiveness by Disease Indication, 2023 to 2033

Figure 147: Eastern Europe Market Attractiveness by Age Group , 2023 to 2033

Figure 148: Eastern Europe Market Attractiveness by Gender, 2023 to 2033

Figure 149: Eastern Europe Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 150: Eastern Europe Market Attractiveness by Country, 2023 to 2033

Figure 151: South Asia and Pacific Market Value (US$ Million) by Treatment Type, 2023 to 2033

Figure 152: South Asia and Pacific Market Value (US$ Million) by Disease Indication, 2023 to 2033

Figure 153: South Asia and Pacific Market Value (US$ Million) by Age Group , 2023 to 2033

Figure 154: South Asia and Pacific Market Value (US$ Million) by Gender, 2023 to 2033

Figure 155: South Asia and Pacific Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 156: South Asia and Pacific Market Value (US$ Million) by Country, 2023 to 2033

Figure 157: South Asia and Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 158: South Asia and Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 159: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 160: South Asia and Pacific Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033

Figure 161: South Asia and Pacific Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033

Figure 162: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033

Figure 163: South Asia and Pacific Market Value (US$ Million) Analysis by Disease Indication, 2018 to 2033

Figure 164: South Asia and Pacific Market Value Share (%) and BPS Analysis by Disease Indication, 2023 to 2033

Figure 165: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Disease Indication, 2023 to 2033

Figure 166: South Asia and Pacific Market Value (US$ Million) Analysis by Age Group , 2018 to 2033

Figure 167: South Asia and Pacific Market Value Share (%) and BPS Analysis by Age Group , 2023 to 2033

Figure 168: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Age Group , 2023 to 2033

Figure 169: South Asia and Pacific Market Value (US$ Million) Analysis by Gender, 2018 to 2033

Figure 170: South Asia and Pacific Market Value Share (%) and BPS Analysis by Gender, 2023 to 2033

Figure 171: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Gender, 2023 to 2033

Figure 172: South Asia and Pacific Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 173: South Asia and Pacific Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 174: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 175: South Asia and Pacific Market Attractiveness by Treatment Type, 2023 to 2033

Figure 176: South Asia and Pacific Market Attractiveness by Disease Indication, 2023 to 2033

Figure 177: South Asia and Pacific Market Attractiveness by Age Group , 2023 to 2033

Figure 178: South Asia and Pacific Market Attractiveness by Gender, 2023 to 2033

Figure 179: South Asia and Pacific Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 180: South Asia and Pacific Market Attractiveness by Country, 2023 to 2033

Figure 181: East Asia Market Value (US$ Million) by Treatment Type, 2023 to 2033

Figure 182: East Asia Market Value (US$ Million) by Disease Indication, 2023 to 2033

Figure 183: East Asia Market Value (US$ Million) by Age Group , 2023 to 2033

Figure 184: East Asia Market Value (US$ Million) by Gender, 2023 to 2033

Figure 185: East Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 186: East Asia Market Value (US$ Million) by Country, 2023 to 2033

Figure 187: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 188: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 189: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 190: East Asia Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033

Figure 191: East Asia Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033

Figure 192: East Asia Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033

Figure 193: East Asia Market Value (US$ Million) Analysis by Disease Indication, 2018 to 2033

Figure 194: East Asia Market Value Share (%) and BPS Analysis by Disease Indication, 2023 to 2033

Figure 195: East Asia Market Y-o-Y Growth (%) Projections by Disease Indication, 2023 to 2033

Figure 196: East Asia Market Value (US$ Million) Analysis by Age Group , 2018 to 2033

Figure 197: East Asia Market Value Share (%) and BPS Analysis by Age Group , 2023 to 2033

Figure 198: East Asia Market Y-o-Y Growth (%) Projections by Age Group , 2023 to 2033

Figure 199: East Asia Market Value (US$ Million) Analysis by Gender, 2018 to 2033

Figure 200: East Asia Market Value Share (%) and BPS Analysis by Gender, 2023 to 2033

Figure 201: East Asia Market Y-o-Y Growth (%) Projections by Gender, 2023 to 2033

Figure 202: East Asia Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 203: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 204: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 205: East Asia Market Attractiveness by Treatment Type, 2023 to 2033

Figure 206: East Asia Market Attractiveness by Disease Indication, 2023 to 2033

Figure 207: East Asia Market Attractiveness by Age Group , 2023 to 2033

Figure 208: East Asia Market Attractiveness by Gender, 2023 to 2033

Figure 209: East Asia Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 210: East Asia Market Attractiveness by Country, 2023 to 2033

Figure 211: Middle East and Africa Market Value (US$ Million) by Treatment Type, 2023 to 2033

Figure 212: Middle East and Africa Market Value (US$ Million) by Disease Indication, 2023 to 2033

Figure 213: Middle East and Africa Market Value (US$ Million) by Age Group , 2023 to 2033

Figure 214: Middle East and Africa Market Value (US$ Million) by Gender, 2023 to 2033

Figure 215: Middle East and Africa Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 216: Middle East and Africa Market Value (US$ Million) by Country, 2023 to 2033

Figure 217: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 218: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 219: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 220: Middle East and Africa Market Value (US$ Million) Analysis by Treatment Type, 2018 to 2033

Figure 221: Middle East and Africa Market Value Share (%) and BPS Analysis by Treatment Type, 2023 to 2033

Figure 222: Middle East and Africa Market Y-o-Y Growth (%) Projections by Treatment Type, 2023 to 2033

Figure 223: Middle East and Africa Market Value (US$ Million) Analysis by Disease Indication, 2018 to 2033

Figure 224: Middle East and Africa Market Value Share (%) and BPS Analysis by Disease Indication, 2023 to 2033

Figure 225: Middle East and Africa Market Y-o-Y Growth (%) Projections by Disease Indication, 2023 to 2033

Figure 226: Middle East and Africa Market Value (US$ Million) Analysis by Age Group , 2018 to 2033

Figure 227: Middle East and Africa Market Value Share (%) and BPS Analysis by Age Group , 2023 to 2033

Figure 228: Middle East and Africa Market Y-o-Y Growth (%) Projections by Age Group , 2023 to 2033

Figure 229: Middle East and Africa Market Value (US$ Million) Analysis by Gender, 2018 to 2033

Figure 230: Middle East and Africa Market Value Share (%) and BPS Analysis by Gender, 2023 to 2033

Figure 231: Middle East and Africa Market Y-o-Y Growth (%) Projections by Gender, 2023 to 2033

Figure 232: Middle East and Africa Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 233: Middle East and Africa Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 234: Middle East and Africa Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 235: Middle East and Africa Market Attractiveness by Treatment Type, 2023 to 2033

Figure 236: Middle East and Africa Market Attractiveness by Disease Indication, 2023 to 2033

Figure 237: Middle East and Africa Market Attractiveness by Age Group , 2023 to 2033

Figure 238: Middle East and Africa Market Attractiveness by Gender, 2023 to 2033

Figure 239: Middle East and Africa Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 240: Middle East and Africa Market Attractiveness by Country, 2023 to 2033

Recommendations

Healthcare

Infection Control Market

Published : September 2022

Healthcare

Diabetes Care Devices Market

Published : July 2022

Explore Healthcare Insights

View Reports

Onychomycosis Treatment Market